Article
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
The Journal of clinical investigation - 17 Jan 2023
Wang Shidan, Rong Ruichen, Yang Donghan M, Fujimoto Junya, Bishop Justin A, Yan Shirley, Cai Ling, Behrens Carmen, Berry Lynne D, Wilhelm Clare, Aisner Dara, Sholl Lynette, Johnson Bruce E, Kwiatkowski David J, Wistuba Ignacio I, Bunn Paul A, Minna John, Xiao Guanghua, Kris Mark G, Xie Yang
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective for many patients with lung cancer with EGFR mutations. However, not all patients are responsive to EGFR TKIs, including even those harboring EGFR-sensitizing mutations. In this study, we quantified the cells and cellular interaction features of the tumor microenvironment (TME) using routine H&E-stained biopsy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.